WO2010072209A3 - Nahrungsergänzungsmittel auf der basis von pantothensäure - Google Patents

Nahrungsergänzungsmittel auf der basis von pantothensäure Download PDF

Info

Publication number
WO2010072209A3
WO2010072209A3 PCT/DE2009/001793 DE2009001793W WO2010072209A3 WO 2010072209 A3 WO2010072209 A3 WO 2010072209A3 DE 2009001793 W DE2009001793 W DE 2009001793W WO 2010072209 A3 WO2010072209 A3 WO 2010072209A3
Authority
WO
WIPO (PCT)
Prior art keywords
pantothenic acid
coa
uptake
food
precursors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2009/001793
Other languages
English (en)
French (fr)
Other versions
WO2010072209A2 (de
Inventor
Hans-Dieter Minge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP09832689A priority Critical patent/EP2378900A2/de
Priority to US13/141,445 priority patent/US20110313041A1/en
Publication of WO2010072209A2 publication Critical patent/WO2010072209A2/de
Publication of WO2010072209A3 publication Critical patent/WO2010072209A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)

Abstract

Die Erfindung betrifft ein Nahrungsergänzungsmittel zur Behebung von Stoffwechselleistungsschwäche enthaltend Pantothensäure (CoA), ihre Vorformen und/oder ihre Salze sowie ein Verfahren zu dessen Herstellung und seine Verwendung. Anwendungsgebiete der Erfindung sind die Nahrungsmittelindustrie und die Medizin. Der Erfindung liegt die überraschende Entdeckung zugrunde, dass sich die Aufnahme von Pantothensäure, Pantothensäure-CoA und/oder seine Derivate in großer Menge vorteilhaft auf Symptome auswirken, die durch Stoffwechselschwäche bedingt sind. Der Kern der Erfindung liegt darin, dass die Aufnahme eines Pantothensäure-CoA Äquivalents aus der Nahrung nicht 10 mg je Tag, sondern mehr als das 103fache betragen muss, um den menschlichen Organismus optimal zu versorgen. Überraschend war ebenfalls der Fund, dass die cholinerge Panthenol-CoA- Aufnahmereaktion aus Speise binnen einiger Minuten erfolgte. Das erfindungsgemäße Nahrungsergänzungsmittel umfasst 85-99% Pantothensäure, ihre Vorläufer, ihre Derivate und/oder ihre Salze und gegebenenfalls weitere Zusätze.
PCT/DE2009/001793 2008-12-23 2009-12-22 Nahrungsergänzungsmittel auf der basis von pantothensäure Ceased WO2010072209A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09832689A EP2378900A2 (de) 2008-12-23 2009-12-22 Nahrungsergänzungsmittel auf der basis von pantothensäure
US13/141,445 US20110313041A1 (en) 2008-12-23 2009-12-22 Food supplements on the basis of pantothenic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008064588.5 2008-12-23
DE102008064588A DE102008064588A1 (de) 2008-12-23 2008-12-23 Nahrungsergänzungsmittel auf der Basis von Pantothensäure

Publications (2)

Publication Number Publication Date
WO2010072209A2 WO2010072209A2 (de) 2010-07-01
WO2010072209A3 true WO2010072209A3 (de) 2010-10-21

Family

ID=42194229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2009/001793 Ceased WO2010072209A2 (de) 2008-12-23 2009-12-22 Nahrungsergänzungsmittel auf der basis von pantothensäure

Country Status (4)

Country Link
US (1) US20110313041A1 (de)
EP (1) EP2378900A2 (de)
DE (1) DE102008064588A1 (de)
WO (1) WO2010072209A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145225A2 (en) * 2015-03-10 2016-09-15 Little Jack E Neuromuscular aid
CN110366642B (zh) 2017-01-19 2022-04-29 宜家供应有限公司 锚固连接器元件的方法、用于实现该方法的机器和连接器元件锚固套件
JP7250810B2 (ja) * 2018-04-25 2023-04-03 オンコクロス カンパニー，リミテッド 筋肉疾患の予防及び治療用組成物
WO2020257279A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders
CN112791076A (zh) * 2021-01-25 2021-05-14 深圳大学 肠道菌落调节剂及其应用
DE102023002534A1 (de) 2023-06-22 2024-12-24 victorioso nutrition UG (haftungsbeschränkt) Oral anzuwendender Mundbeutel, Mischungen und Verwendung derselben

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003482A1 (en) * 1997-07-19 1999-01-28 Edwina Margaret Piper Mineral and vitamin combinations for the treatment of stress and allergies
WO2006108208A1 (en) * 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
JP2008143811A (ja) * 2006-12-07 2008-06-26 Nisshin Pharma Inc 脂質代謝促進組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE572009A (de) * 1957-10-15
GB1033843A (en) * 1964-05-26 1966-06-22 Eustace Cecil Barton Wright Pharmaceutical composition for treating thermatoid arthritis
GB8922701D0 (en) * 1989-10-09 1989-11-22 Leung Lit Hung Compositions and methods for weight reduction
GB2252905B (en) 1991-02-11 1995-05-10 Leung Lit Hung An agent for correcting a deficiency of androgenic steroids
WO2005041949A1 (en) * 2003-10-30 2005-05-12 Howard James R Composition for the treatment of dysfunctional energy metabolism syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003482A1 (en) * 1997-07-19 1999-01-28 Edwina Margaret Piper Mineral and vitamin combinations for the treatment of stress and allergies
WO2006108208A1 (en) * 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
JP2008143811A (ja) * 2006-12-07 2008-06-26 Nisshin Pharma Inc 脂質代謝促進組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCCARTY M F: "Hepatothermic therapy of obesity: Rationale and an inventory of resources", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US LNKD- DOI:10.1054/MEHY.2000.1322, vol. 57, no. 3, 1 January 2001 (2001-01-01), pages 324 - 336, XP009030758, ISSN: 0306-9877 *
RAMAN S B: "Pantothenate synthesis in plants", PLANT SCIENCE, vol. 167, 10 July 2004 (2004-07-10), pages 961 - 968, XP002594954 *

Also Published As

Publication number Publication date
US20110313041A1 (en) 2011-12-22
DE102008064588A1 (de) 2010-06-24
WO2010072209A2 (de) 2010-07-01
EP2378900A2 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
WO2013153071A3 (en) A nutritional composition
WO2010072209A3 (de) Nahrungsergänzungsmittel auf der basis von pantothensäure
EP2536736A4 (de) Herstellung von 6'-o-sialyllactose und zwischenprodukten davon
EP4556073A3 (de) Verfahren zur verringerung des risikos eines kardiovaskulären ereignisses bei einer person auf einer statintherapie
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
WO2012094598A3 (en) Pharmaceutical compositions of iron for oral administration
JO2927B1 (en) Dian cyanopyridines are substituted with alkyl amino and the primary amino acid ester drugs
GB2459809A (en) Fatty acid formulations and methods of use thereof
MX341151B (es) Composiciones para reducir la metanogenesis gastrointestinal en rumiantes.
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
MX342733B (es) Composicion nutricional para promover el desarrollo y crecimiento sano.
WO2007117706A3 (en) Solid oral dosage form containing an enhancer
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MY176863A (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
EP2576578A4 (de) Polymorphe von 2'-o-fucosyllactose und herstellung davon
WO2007103160A3 (en) Stearidonic acid for improving cardiovascular health
WO2011149713A3 (en) Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
MX2010009883A (es) Acidos dicarboxilicos de cadena media, sus derivados y enfermedades metabolicas.
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
MX351037B (es) Composiciones de goma humectantes de la boca y productos que contienen las mismas.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same

Legal Events

Date Code Title Description
REEP Request for entry into the european phase

Ref document number: 2009832689

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009832689

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13141445

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832689

Country of ref document: EP

Kind code of ref document: A2